Merck (MRK) Granted FDA Approval of KEYTRUDA (pembrolizumab) for Adult & Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
